We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the EU, biosimilars are poised to join the main market as prescribers widely embrace the lower-cost, copycat versions of the brand-name drugs. Read More
The FDA has asked for more information on the pen injector device used in Sanofi and Zealand Pharma’s IGlarLixi combination product for diabetes, extending its review by three months. Read More
Almost a year after Bayer settled pay-for-delay allegations involving its antibiotic Cipro, Ireland-based Allergan and France-based Sanofi units have struck deals to resolve lingering Cipro claims in ongoing class action litigation, agreeing to pony up $100 million. Read More